1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Xydalba: new trials by email Literature Review of Xydalba trials Research Report on Xydalba
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Dalbavancin, Vancomycin, Oxacillin - Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Completed | AbbVie | 199 | 2017-03-30 | 2024-09-19 |
Bacterial Infections (1) · Staphylococcal Skin Infections (1)
AbbVie (1)
Argentina (1) · Belarus (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · Georgia (1) · Greece (1) · Guatemala (1) · Latvia (1) · Lithuania (1) · Mexico (1) · Panama (1) · Poland (1) · Romania (1)
2014 (1)